Gene Expression Profile Testing in Skin Cancer Prognosis: The Data is Clear – It’s Time to Get On Board
Main Article Content
Keywords
Gene Expression Profile, Skin Cancer, Melanoma, Melanoma Prognosis, 31-GEP
Abstract
Abstract not available.
References
Elmore JG, Elder DE, Barnhill RL, et al. Concordance and Reproducibility of Melanoma Staging According to the 7th vs 8th Edition of the AJCC Cancer Staging Manual. JAMA Netw Open. 2018;1(1):e180083. doi:10.1001/jamanetworkopen.2018.0083
Ferguson PM, Gershenwald JE, Scolyer RA. Staging of Cutaneous Melanoma: Is There Room for Further Improvement? JAMA Netw Open. 2018;1(1):e180086. doi:10.1001/jamanetworkopen.2018.0086
Greenhaw BN, Covington KR, Kurley SJ, Yeniay Y, Cao NA, Plasseraud KM, Cook RW, Hsueh EC, Gastman BR, Wei ML, Molecular risk prediction in cutaneous melanoma: a metaanalysis of the 31-gene expression profile prognostic test in 1,479 patients, Journal of the American Academy of Dermatology (2020), doi.org/10.1016/j.jaad.2020.03.053.
Litchman G, Prado G, Teplitz R, Rigel DS. A Systematic Review and Meta-Analysis of Gene Expression Profiling for Primary Cutaneous Melanoma Prognosis. SKIN J Cutan Med, 2020 May vol 4(3):221-237. doi: 10.25251/skin.4.3.3
Bax MJ, Johnson TM, Harms PW, Schwartz JL, Zhao L, Fullen DR, Chan MP. Detection of Occult Invasion in Melanoma In Situ. JAMA Dermatol. 2016 Nov 1;152(11):1201-1208. doi: 10.1001/jamadermatol.2016.2668.
Ferris LK, Farberg AS, Middlebrook B, Johnson CE, Lassen N, Oelschlager KM, Maetzold DJ, Cook RW, Rigel DS, Gerami P. Identification of high-risk cutaneous melanoma tumors is improved when combining the online American Joint Committee on Cancer Individualized Melanoma Patient Outcome Prediction Tool with a 31-gene
expression profile-based classification. J Am Acad Dermatol. 2017 May;76(5):818-825.e3. doi: 10.1016/j.jaad.2016.11.051.
Vetto JT, Hsueh EC, Gastman BR, Dillon LD, Monzon FA, Cook RW, Keller J, Huang X, Fleming A, Hewgley P, Gerami P, Leachman S, Wayne JD, Berger AC, Fleming MD. Guidance of sentinel lymph node biopsy decisions in patients with T1-T2 melanoma using gene expression profiling. Future Oncol. 2019 Apr;15(11):1207-1217. doi:
10.2217/fon-2018-0912.
Farberg AS, Glazer AM, White R, Rigel DS. Impact of a 31-gene Expression Profiling Test for Cutaneous Melanoma on Dermatologists' Clinical Management Decisions. J Drugs Dermatol. 2017;16(5):428-431.
Landow SM, Gjelsvik A, Weinstock MA. Mortality burden and prognosis of thin melanomas overall and by subcategory of thickness, SEER registry data, 1992-2013. J Am Acad Dermatol. 2017 Feb;76(2):258-263. doi: 10.1016/j.jaad.2016.10.018. Epub
2016 Nov 22.
Gastman B, Gerami P, Kurley S, Cook R, Leachman S, Vetto J. Identification of patients at risk of metastasis using a prognostic 31-gene expression profile in subpopulations of melanoma patients with favorable outcomes by standard criteria. J Am Acad Dermatol 2019;80:149-57.
Swetter SM, et. al. NCCN Clinical Practice Guidelines in Oncology: Cutaneous Melanoma. April 9, 2020. National Comprehensive Cancer Network; 2020.
Kovarik C, Chu E, Adamson A. Gene Expression Profile Testing for Thin Melanoma; Evidence to Support Clinical Use Remains Thin. JAMA Dermatol 2020 Online publication.
Mathes T, Pieper D. An algorithm for the classification of study designs to assess diagnostic, prognostic and predictive test accuracy in systematic reviews. Systematic Reviews. 2019 Sep;8(1):226. DOI: 10.1186/s13643-019-1131-4.
Berman, B., Ceilley, R., Cockerell, C., Ferris, L., High, W., Lebwohl, M., Nestor, M., Rosen, T., Litchman, G., Prado, G., Svoboda, R., & Rigel, D. (2019). Appropriate Use Criteria for the Integration of Diagnostic and Prognostic Gene Expression Profile Assays into the Management of Cutaneous Malignant Melanoma: An Expert Panel Consensus-Based Modified Delphi Process Assessment. SKIN The Journal of Cutaneous Medicine, 2019;3(5), 291-306. doi:https://doi.org/10.25251/skin.3.5.1
Marks, E., Caruso, H., Kurley, S., Ibad, S., Plasseraud, K., Monzon, F., & Cockerell, C. (2019). Establishing an evidence-based decision point for clinical use of the 31-gene expression profile test in cutaneous melanoma. SKIN The Journal of Cutaneous Medicine, 2019;3(4), 239-249. doi:https://doi.org/10.25251/skin.3.4.2
Wysong A, Newman JG, Covington KR, Kurley SJ, Ibrahim SF, Farberg AS, Bar A, Cleaver NJ, Somani AK, Panther D, Brodland DG, Zitelli J, Toyohara J, Maher IA, Xia Y, Bibee K, Griego R, Rigel DS, Plasseraud KM, Estrada S, Sholl LM, Johnson C, Cook RW, Schmults CD, Arron ST. Validation of a 40-Gene Expression Profile Test to Predict Metastatic Risk in Localized High-Risk Cutaneous Squamous Cell Carcinoma. J Am Acad Dermatol. 2020 Apr 25. pii: S0190-9622(20)30704-0. doi:10.1016/j.jaad.2020.04.088.
Ferguson PM, Gershenwald JE, Scolyer RA. Staging of Cutaneous Melanoma: Is There Room for Further Improvement? JAMA Netw Open. 2018;1(1):e180086. doi:10.1001/jamanetworkopen.2018.0086
Greenhaw BN, Covington KR, Kurley SJ, Yeniay Y, Cao NA, Plasseraud KM, Cook RW, Hsueh EC, Gastman BR, Wei ML, Molecular risk prediction in cutaneous melanoma: a metaanalysis of the 31-gene expression profile prognostic test in 1,479 patients, Journal of the American Academy of Dermatology (2020), doi.org/10.1016/j.jaad.2020.03.053.
Litchman G, Prado G, Teplitz R, Rigel DS. A Systematic Review and Meta-Analysis of Gene Expression Profiling for Primary Cutaneous Melanoma Prognosis. SKIN J Cutan Med, 2020 May vol 4(3):221-237. doi: 10.25251/skin.4.3.3
Bax MJ, Johnson TM, Harms PW, Schwartz JL, Zhao L, Fullen DR, Chan MP. Detection of Occult Invasion in Melanoma In Situ. JAMA Dermatol. 2016 Nov 1;152(11):1201-1208. doi: 10.1001/jamadermatol.2016.2668.
Ferris LK, Farberg AS, Middlebrook B, Johnson CE, Lassen N, Oelschlager KM, Maetzold DJ, Cook RW, Rigel DS, Gerami P. Identification of high-risk cutaneous melanoma tumors is improved when combining the online American Joint Committee on Cancer Individualized Melanoma Patient Outcome Prediction Tool with a 31-gene
expression profile-based classification. J Am Acad Dermatol. 2017 May;76(5):818-825.e3. doi: 10.1016/j.jaad.2016.11.051.
Vetto JT, Hsueh EC, Gastman BR, Dillon LD, Monzon FA, Cook RW, Keller J, Huang X, Fleming A, Hewgley P, Gerami P, Leachman S, Wayne JD, Berger AC, Fleming MD. Guidance of sentinel lymph node biopsy decisions in patients with T1-T2 melanoma using gene expression profiling. Future Oncol. 2019 Apr;15(11):1207-1217. doi:
10.2217/fon-2018-0912.
Farberg AS, Glazer AM, White R, Rigel DS. Impact of a 31-gene Expression Profiling Test for Cutaneous Melanoma on Dermatologists' Clinical Management Decisions. J Drugs Dermatol. 2017;16(5):428-431.
Landow SM, Gjelsvik A, Weinstock MA. Mortality burden and prognosis of thin melanomas overall and by subcategory of thickness, SEER registry data, 1992-2013. J Am Acad Dermatol. 2017 Feb;76(2):258-263. doi: 10.1016/j.jaad.2016.10.018. Epub
2016 Nov 22.
Gastman B, Gerami P, Kurley S, Cook R, Leachman S, Vetto J. Identification of patients at risk of metastasis using a prognostic 31-gene expression profile in subpopulations of melanoma patients with favorable outcomes by standard criteria. J Am Acad Dermatol 2019;80:149-57.
Swetter SM, et. al. NCCN Clinical Practice Guidelines in Oncology: Cutaneous Melanoma. April 9, 2020. National Comprehensive Cancer Network; 2020.
Kovarik C, Chu E, Adamson A. Gene Expression Profile Testing for Thin Melanoma; Evidence to Support Clinical Use Remains Thin. JAMA Dermatol 2020 Online publication.
Mathes T, Pieper D. An algorithm for the classification of study designs to assess diagnostic, prognostic and predictive test accuracy in systematic reviews. Systematic Reviews. 2019 Sep;8(1):226. DOI: 10.1186/s13643-019-1131-4.
Berman, B., Ceilley, R., Cockerell, C., Ferris, L., High, W., Lebwohl, M., Nestor, M., Rosen, T., Litchman, G., Prado, G., Svoboda, R., & Rigel, D. (2019). Appropriate Use Criteria for the Integration of Diagnostic and Prognostic Gene Expression Profile Assays into the Management of Cutaneous Malignant Melanoma: An Expert Panel Consensus-Based Modified Delphi Process Assessment. SKIN The Journal of Cutaneous Medicine, 2019;3(5), 291-306. doi:https://doi.org/10.25251/skin.3.5.1
Marks, E., Caruso, H., Kurley, S., Ibad, S., Plasseraud, K., Monzon, F., & Cockerell, C. (2019). Establishing an evidence-based decision point for clinical use of the 31-gene expression profile test in cutaneous melanoma. SKIN The Journal of Cutaneous Medicine, 2019;3(4), 239-249. doi:https://doi.org/10.25251/skin.3.4.2
Wysong A, Newman JG, Covington KR, Kurley SJ, Ibrahim SF, Farberg AS, Bar A, Cleaver NJ, Somani AK, Panther D, Brodland DG, Zitelli J, Toyohara J, Maher IA, Xia Y, Bibee K, Griego R, Rigel DS, Plasseraud KM, Estrada S, Sholl LM, Johnson C, Cook RW, Schmults CD, Arron ST. Validation of a 40-Gene Expression Profile Test to Predict Metastatic Risk in Localized High-Risk Cutaneous Squamous Cell Carcinoma. J Am Acad Dermatol. 2020 Apr 25. pii: S0190-9622(20)30704-0. doi:10.1016/j.jaad.2020.04.088.
Article Sidebar
Published
Jul 12, 2020
Article Details
How to Cite
Rigel, D. S., Ceilley, R. I., Litchman, G. H., & Cockerell, C. J. (2020). Gene Expression Profile Testing in Skin Cancer Prognosis: The Data is Clear – It’s Time to Get On Board. SKIN The Journal of Cutaneous Medicine, 4(4), 304–308. https://doi.org/10.25251/skin.4.4.1
Issue
Section
Editorials
This work is licensed under a Creative Commons Attribution 4.0 International License.
All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by the following user license:
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.
Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.